Sanofi Consumer Healthcare India Limited reported a 21% increase in revenue from operations to ₹8,784 million for the financial year ended December 31, 2025. Profit after tax grew by 33% to ₹2,401 million, while return on capital employed stood at 62.5%. The company’s export business expanded its geographic footprint during the year.

The company’s performance reflects the strength of its brands, the effectiveness of its growth investments, and operational discipline. During the year, the company made deliberate investments behind its brands, supported by a synergistic demand-generation model that integrated Healthcare Professional (HCP) recommendation, consumer engagement, and retail availability.

Financial Performance

The company delivered a strong financial performance despite operating in a dynamic environment. The export business continued to gain momentum, expanding both geographic footprint and growth opportunities. This progress strengthens the diversification of the business and enhances the ability to leverage the strength of brands beyond India.

Strategic Initiatives

The company significantly expanded its engagement with doctors and specialists, doubling its face-to-face doctor reach and extending its digital HCP engagement to over 50,000 healthcare professionals. Consumer engagement initiatives reached approximately 60 million consumers through digital-first, multimedia campaigns.

The company also strengthened its innovation agenda with the launch of Allegra-D, a differentiated and efficacious solution that addresses an important consumer need. The launch reinforces the commitment to bringing science-backed innovations that deliver meaningful health outcomes for consumers.

Corporate Governance

The Board of Directors has recommended a final dividend of ₹75 per equity share of ₹10 each for the financial year ended December 31, 2025. The dividend is subject to the approval of members at the ensuing Annual General Meeting scheduled on June 26, 2026.

The company has appointed M/s. Price Waterhouse & Co Chartered Accountants LLP as the statutory auditors to fill the casual vacancy caused by the resignation of M/s. Kalyaniwalla & Mistry LLP. The appointment is subject to shareholder approval.

Sanofi Consumer Healthcare India Limited has fixed June 19, 2026, as the record date for the payment of the final dividend. Shareholders registered on this date will be eligible for the payout. The company has scheduled its 3rd Annual General Meeting (AGM) for June 26, 2026, at 3:00 p.m. IST, which will be conducted through video conferencing and other audio-visual means in compliance with circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India.

Pursuant to Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015, the Register of Members and Share Transfer Books will remain closed from June 20, 2026, to June 26, 2026. This closure applies to both days inclusive. The payment of the final dividend will be made to members whose names appear on the Register of Members on the record date or as beneficial owners at the close of business hours on June 19, 2026, as per details furnished by depositories NSDL and CDSL.

The Annual Report for the Financial Year 2025, along with the Notice convening the AGM, will be dispatched to shareholders in due course. The intimation was signed by Nikunj Kumar Savaliya, Company Secretary and Compliance Officer.